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BRIEF COMMUNICATION
Unique Transcriptome Signature 
Distinguishes Patients With Heart Failure 
With Myopathy
Talia Caspi , MBChB*; Sam Straw , MBChB*; Chew Cheng , PhD*; Jack O Garnham, PhD;  
Jason L. Scragg, PhD; Jessica Smith, PhD; Aaron O. Koshy, MBChB; Eylem Levelt, PhD; Piruthivi Sukumar , 
MD; John Gierula, PhD; David J. Beech, PhD; Mark T. Kearney , MD; Richard M. Cubbon , PhD;  
Stephen B. Wheatcroft, PhD; Klaus K. Witte , MD; Lee D. Roberts, PhD; T. Scott Bowen , PhD
BACKGROUND: People with chronic heart failure (CHF) experience severe skeletal muscle dysfunction, characterized by mito-
chondrial abnormalities, which exacerbates the primary symptom of exercise intolerance. However, the molecular triggers and 
characteristics underlying mitochondrial abnormalities caused by CHF remain poorly understood.
METHODS AND RESULTS: We recruited 28 patients with CHF caused by reduced ejection fraction and 9 controls. We simultane-
ously biopsied skeletal muscle from the pectoralis major in the upper limb and from the vastus lateralis in the lower limb. We 
phenotyped mitochondrial function in permeabilized myofibers from both sites and followed this by complete RNA sequenc-
ing to identify novel molecular abnormalities in CHF skeletal muscle. Patients with CHF presented with upper and lower limb 
skeletal muscle impairments to mitochondrial function that were of a similar deficit and indicative of a myopathy. Mitochondrial 
abnormalities were strongly correlated to symptoms. Further RNA sequencing revealed a unique transcriptome signature in 
CHF skeletal muscle characterized by a novel triad of differentially expressed genes related to deficits in energy metabolism 
including adenosine monophosphate deaminase 3, pyridine nucleotide-disulphide oxidoreductase domain 2, and lactate 
dehydrogenase C.
CONCLUSIONS: Our data suggest an upper and lower limb metabolic myopathy that is characterized by a unique transcriptome 
signature in skeletal muscle of humans with CHF.
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People with chronic heart failure (CHF) caused by reduced left ventricular ejection fraction (ie, heart failure with reduced ejection fraction) 
develop significant skeletal muscle abnormalities 
underpinned by impaired mitochondrial energy me-
tabolism, which more closely correlate to symptoms 
than to the degree of cardiac dysfunction.1 Improved 
skeletal muscle mitochondrial function in CHF is as-
sociated with alleviation of symptoms and improved 
quality of life, and is considered a worthy therapeutic 
target.2 However, controversy remains as to whether 
muscle mitochondrial abnormalities in CHF are cen-
tral to the disease process or occur secondary to 
detraining.3 Most studies in patients with CHF have 
used thigh biopsies to investigate mitochondrial dys-
function,1 while few studies have used alternative 
sample sites that are unlikely impacted by detraining. 
Yet, various upper limb muscles (eg, pectoralis major 
and diaphragm) in patients with CHF exhibit histo-
logical perturbations similar to (or even greater than) 
the lower limbs (eg, vastus lateralis).1 The pectoralis 
major also demonstrates mitochondrial dysfunction4 
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alongside muscle atrophy that independently pre-
dicts mortality in patients with CHF.2 This evidence 
provides support for a myopathy in patients with CHF 
independent of detraining.
The mechanisms underpinning mitochondrial 
dysfunction in CHF remain poorly defined. Putative 
mechanisms specific to the disease include impaired 
energy homeostasis via dysregulation in high energy 
phosphates (eg, ATP, ADP, and AMP), activation of 
atrophic signaling networks involved in protein deg-
radation, elevated inflammatory cytokines and reac-
tive O2 species that disrupt cellular homeostasis, and 
abnormal microvascular homeostasis.1 Yet, many of 
these hypotheses have been investigated in animal 
models rather than human tissue. Whole transcrip-
tome RNA sequencing (RNA-seq) has been applied 
in people with diabetes mellitus,5 critical illness,6 pe-
ripheral arterial disease,7 disuse,8 and aging9 to re-
veal novel molecular mechanisms of skeletal muscle 
abnormalities. However, to our knowledge, the mo-
lecular signature of skeletal muscle in patients with 
CHF has yet to be investigated.
Here, we recruited a total of 28 patients with CHF 
and 9 controls. We simultaneously biopsied skeletal 
muscle from the pectoralis major (PM) in the upper 
limb and from the vastus lateralis (VL) in the lower 
limb. Mitochondrial function was phenotyped in my-
ofibers from both sites using high-resolution respi-
rometry to determine whether upper and lower limb 
impairments were present and their association with 
symptoms. We then applied RNA-seq to identify 
underlying molecular abnormalities of muscle dys-
function in patients with CHF. Overall, we found that 
patients with CHF present with a similar degree of 
mitochondrial dysfunction in both the PM and VL, 
indicative of a myopathy. RNA-seq analysis identi-
fied a triad of differentially expressed genes related 
to impaired mitochondrial energy metabolism. We 
believe our data reveal, for the first time, a unique 
transcriptome signature in skeletal muscle of humans 
with CHF.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon rea-
sonable request. Clinical characteristics and medica-
tions for all patients are presented in Tables S1 and S2, 
respectively. Patients were allocated to control (n=9) 
or CHF (n=28) groups. Controls had no clinical evi-
dence of CHF: left ventricular ejection fraction ≥50% 
and no previous diagnosis of left ventricular systolic 
dysfunction. Patients with CHF had stable symptoms 
of CHF (>3  months on medical therapy) and a left 
ventricular ejection fraction <50% as confirmed by 
transthoracic echocardiography (following current 
European Society of Cardiology guidelines). All par-
ticipants were indicated for device therapy with either 
a permanent pacemaker, implantable cardioverter-
defibrillator, or cardiac resynchronization therapy de-
vice according to current indications. Patients with 
CHF performed a peak symptom-limited exercise 
test to volitional exhaustion on a cycle ergometer for 
determination of peak pulmonary O2 uptake (V̇O2peak
). Exclusion criteria included inability to provide in-
formed consent because of cognitive dysfunction or 
the presence of previous diagnoses with other po-
tentially confounding comorbidities, such as chronic 
obstructive pulmonary disease or cancer. All patients 
provided written informed consent and all procedures 
were conducted in accordance with the Declaration 
of Helsinki after receiving local institute ethical ap-
proval (11/YH/0291).
Muscle Biopsy, Mitochondrial Respiration, 
and RNA-Seq
Muscle samples were taken from 2 sites in partici-
pants: the upper limb (PM) and lower limb (VL). The PM 
sample was obtained during routine device implanta-
tion procedures, while on the same day the VL sample 
was from the right thigh. One piece of fresh muscle 
sample was used for the assessment of mitochondrial 
respiration,4 while another small portion was rapidly 
frozen in a subset of patients (controls=3, CHF=6) for 
subsequent RNA-seq analysis.10 See Data S1 for ex-
panded details.
Statistical Analysis
Assumption of homogeneity of variance was confirmed 
using Levene test, while Shapiro-Wilk and Kolmogorov–
Smirnov normality tests confirmed normal (Gaussian) 
distribution. Unpaired Student t test was used to com-
pare between-group differences, while paired Student 
t test was used for within-group comparisons for con-
tinuous data and chi-square test for categorical data. 
Further, ANCOVA was performed to adjust for the vari-
ables of age and sex. Pearson correlation coefficient 
(r) was performed to assess the association between 
mitochondrial respiration at different muscle sites and 
V̇O2peak. Continuous data are expressed as mean±SEM 
and categorical data as number (percentage). Statistical 
significance was accepted as P<0.05.
RESULTS
Mitochondrial Myopathy in Patients With 
CHF
We first aimed to confirm the presence of skeletal 
muscle mitochondrial dysfunction in patients with CHF 
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in both upper and lower limb muscle sites. Based on 
published data, we hypothesized that mitochondrial 
dysfunction would occur to a greater degree in the 
lower compared with the upper limbs. We analyzed 
mitochondrial O2 consumption in permeabilized fib-
ers of PM and VL from patients with CHF using high-
resolution respirometry. Mitochondrial O2 flux was, on 
average, lower by 15% to 20% in patients with CHF 
among respiratory states (Figure  1A and 1B). ADP-
stimulated mitochondrial complex I respiration was 
lower in both PM (P=0.028) and VL (P=0.015) by 25% 
and 28%, respectively (Figure 1A and 1B). Convergent 
complex I and II respiration (P=0.047) and complex II 
respiration (P=0.037) were also significantly lower in 
the PM of patients with CHF compared with controls 
by ≈20% (Figure 1A). However, after adjusting for con-
founding variables (specifically age and sex) between 
the 2 groups, differences in mitochondrial respiration 
were not detected (P>0.05). Mitochondrial respiration 
is determined by both organelle quantity and quality. 
A lower mitochondrial content is most often reported 
in patients with CHF.3,11 We therefore assessed in-
trinsic mitochondrial respiration after normalization to 
complex IV activity (a proxy for mitochondrial mass).4 
Here, we observed fewer differences between patients 
and controls (Figure 1C and 1D), with only VL show-
ing an 18% lower complex I respiration versus controls 
(P=0.048, Figure 1D)
Whole-Body Mitochondrial Impairments 
Correlate to Symptoms
Having identified that both upper and lower muscles 
of patients with CHF experience similar reductions in 
mitochondrial respiration, we further characterized 
their clinical importance. We correlated mitochondrial 
deficits in PM and VL to the gold-standard measure of 
whole-body exercise intolerance: peak pulmonary O2 
uptake (VO2peak). We focused on complex I and com-
plex IV respiration, given our earlier findings. Complex 
I respiration was well correlated with VO2peak in PM but 
less so in VL (Figure 1E and 1F), while complex IV res-
piration correlated well with measures in PM but not VL 
(Figure 1G and 1H).
Lower Limbs Demonstrate Greater 
Oxidative Capacity
The PM and VL demonstrated distinct phenotypes in 
correlations between mitochondrial mass and exer-
cise intolerance. Therefore, we compared mitochon-
drial respiration between PM and VL muscle sites in 
patients with CHF for mechanistic insight. Compared 
with PM, patients with CHF demonstrated greater 
mitochondrial O2 flux in VL across respiratory states. 
Both complex I and complex II respiration were ≈30% 
higher in VL versus PM (P<0.001). Mitochondrial con-
tent, as assessed by complex IV respiration, was 
also higher in VL versus PM by ≈40% (Figure  2A). 
We therefore normalized PM and VL respiration to 
mitochondrial content to assess intrinsic respiration. 
PM had higher intrinsic mitochondrial respiration at 
leak (P=0.01) and complex I (P=0.02) compared with 
VL (Figure 2B); however, no differences between the 
respiratory control ratio (RCR) was detected (5.0±0.6 
versus 5.4±0.4, P>0.05). Furthermore, complex I 
respiration was correlated between upper and lower 
limb muscles (r=0.51, P=0.02; Figure 2C). This was 
not observed for complex IV respiration (r=0.22, 
P=0.32; Figure 2D).
RNA-Seq Analysis in Human Heart Failure 
Skeletal Muscle
We have demonstrated that mitochondrial dysfunc-
tion induced by CHF occurs in both the upper and 
lower limbs that closely correlates to symptom se-
verity. Next, we used high-throughput RNA-seq to 
interrogate the molecular alterations accompany-
ing skeletal muscle impairments in CHF (Figure 3A). 
To our knowledge, our study is the first to perform 
whole-transcriptome sequencing in skeletal muscle 
in humans with CHF. RNA-seq was performed on 
PM biopsy from 9 participants (3 controls and 6 CHF, 
Table S3), which generated ≈16 million 75 bp single-
end reads for each individual (Table S4). Only uniquely 
mapped reads were retained for downstream differ-
ential expression analysis. Overall, ≈92% of the reads 
mapped uniquely to the human reference genome 
(GRCh38). RNA integrity number scores were con-
sistently high for all samples (RNA integrity number 
>7.5). The read counts were normalized using median 
of ratios as implemented in DESeq2. The normalized 
gene expression was expressed as read counts for 
all 18  426 genes (Table  S5). To determine whether 
expression profiles among the 9 patients could dis-
criminate them based on the disease status, the data 
set was analyzed using partial least squares discri-
minant analysis. Partial least squares discriminant 
analysis plot distinguished 2 groups of individuals: 
controls and patients with CHF (Figure 3B). The first 
component accounted for 48%, and the second 
component accounted for 21% of the variance in the 
partial least squares discriminant analysis model. 
Interestingly, our transcriptome analysis also ap-
peared to identify 2 distinct clusters of patients with 
CHF (Figure  3B): cluster 1 (n=3; patients 1, 3, and 
4) and cluster 2 (n=3; patients 2, 5, and 6). When 
we further analyzed demographic and clinical char-
acteristics of these 2 clusters (Table  S6) we found 
only left ventricular systolic function to be different 
between the 2 groups, with a lower value in cluster 2 
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Figure 1. Skeletal muscle mitochondrial respiration is impaired in patients with heart failure and 
correlated to exercise intolerance.
Mitochondrial O2 flux measured in myofibers biopsied from pectoralis major (PM) and vastus lateralis (VL) 
of patients with chronic heart failure (CHF) (n=22) and controls (n=6). Mitochondrial respiration in the PM 
and VL is presented between groups in both absolute units (A and B) and normalized to mitochondrial 
content (C and D). Correlations between exercise intolerance (ie, VO2peak) and complex I respiration (E and 
F) and mitochondrial content (ie, complex IV) in CHF (G and H). Leak (LI), complex I (PI), complex I and II 
(PI+II and EI+II), complex II (EII) and complex IV (CIV) measured under oxidative phosphorylation (OXPHOS; 
P), and electron transport system (ETS; E) supported respiration. *P<0.05 between-group comparisons. 
Correlation coefficient (r). Data are mean±SEM.
D
ow
nloaded from
 http://ahajournals.org by on September 11, 2020
J Am Heart Assoc. 2020;9:e017091. DOI: 10.1161/JAHA.120.017091 5
Caspi et al Myopathy in Heart Failure
versus cluster 1 (14%±1% versus 38%±5%, P<0.01; 
Table  S6). Taken together, these data may indicate 
that the degree of left ventricular systolic dysfunction 
is a potential determinant of the skeletal muscle tran-
scriptome in patients with CHF.
Distinct Transcriptome Signature in 
Skeletal Muscle of CHF
From a total of 18 426 genes identified, 3 genes re-
lated to energy metabolism were differentially ex-
pressed genes between control and CHF at a fold 
change >1.5 and false discovery rate threshold <0.05 
(Figure 3C). Two genes were upregulated in CHF: AMP 
deaminase 3 (AMPD3) (log2-fold change=1.62, false 
discovery rate=0.0023) and pyridine nucleotide-di-
sulphide oxidoreductase domain 2 (PYROXD2) (log2-
fold change=1.33, false discovery rate=0.0077), while 
lactate dehydrogenase C (log2-fold change=−5.52, 
false discovery rate=0.0002) was downregulated 
(Figure 3C). Hierarchical clustering illustrated on the 
heat map using the 3 differentially expressed genes 
clearly show 2 distinct branches. In patients with CHF 
we found that lactate dehydrogenase C was consist-
ently downregulated among the 6 patients, while 
AMPD3 and PYROXD2 were upregulated (Figure 3D). 
Overall, whole-transcriptome sequencing revealed a 
novel triad of metabolic genes that are dysregulated 
in skeletal muscle from patients with CHF.
DISCUSSION
This is the first study to demonstrate that skeletal 
muscle from patients with CHF is characterized by 
a unique transcriptome signature that underpins an 
upper and lower limb metabolic myopathy closely 
linked to worse symptoms. We identified a triad of 
genes dysregulated in CHF that are involved in ATP 
homeostasis. These findings have important implica-
tions for our understanding of the link between mus-
cle abnormalities and symptoms in patients with CHF.
Figure 2. Mitochondrial respiration varies between upper and lower limb skeletal muscle in 
patients with heart failure.
Pectoralis major (PM) and vastus lateralis (VL) mitochondrial respiration measured in myofibers of patients 
with chronic heart failure (CHF) (A) and corrected for mitochondrial content (B). Correlations between VL 
and PM complex I function (C) and complex IV function (mitochondrial content) (D). Leak (LI), complex 
I (PI), complex I and II (PI+II and EI+II), complex II (EII) and complex IV (CIV) measured under oxidative 
phosphorylation (OXPHOS; P) and electron transport system (ETS; E) supported respiration. *P<0.05. 
Correlation coefficient (r). Data are mean±SEM.
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Is There a CHF-Associated Myopathy?
Our data highlight that both PM and VL in patients 
with CHF show a similar degree of loss in mitochon-
drial respiratory function (Figure  1A and 1B). This 
upper and lower limb dysfunction appears primarily 
driven by a decrease in mitochondrial volume and 
dysfunction of complex I respiration, which is likely a 
major contributor exacerbating symptoms of fatigue 
in many patients. We speculate that this could re-
flect a mitochondrial myopathy that is independent 
of disuse, which may exacerbate symptoms of ex-
ercise limitation (Figure 1E through 1H). Our findings 
Figure 3. Patients with heart failure are characterized by a distinct skeletal muscle transcriptome 
signature.
RNA-sequence analysis workflow (A), where 9 pectoralis major (PM) human biopsies were obtained (n=3 
controls; n=6 chronic heart failure [CHF]) and RNA samples proceeded with library preparation and RNA 
sequencing. Bioinformatics processing was performed on the raw reads and identified the significantly 
regulated genes in CHF. Partial least squares discriminant analysis (PLS-DA) plot of expression profiles 
for 18  426 genes among the 9 patients, CHF (orange) controls (blue) (B). Volcano plot showing the 3 
significantly regulated genes (red dots), including AMP deaminase 3 (AMPD3) and pyridine nucleotide-
disulphide oxidoreductase domain 2 (PYROXD2) upregulated in CHF and lactate dehydrogenase C (LDHC) 
downregulated (C). Heat map of differentially expressed genes (DEGs) in CHF and control samples (D). 
DEGs in the heat map were clustered based on a hierarchical algorithm implemented in “pheatmap.” 
Heat map was generated with log10-normalized reads derived from DESeq2. Color scale represents log10-
transformed normalized reads.
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further revealed that while mitochondrial capacity is 
higher per muscle mass in the leg, O2 flux normal-
ized per mitochondrial mass (ie, intrinsic function) is 
higher in the chest muscle (Figure 2A and 2B). Thus, 
it seems that the VL has higher mitochondrial mass 
compared with upper limb muscles, which is likely 
a consequence of higher metabolic demands during 
daily activities. This may be important because, un-
like the VL, the PM did not demonstrate reductions 
in intrinsic mitochondrial function versus healthy con-
trols. The close association between O2 flux meas-
urements taken from chest and leg muscle further 
provides validation for the PM being an alternative 
site for investigating muscle dysfunction in patients 
with CHF, which aligns with recent data showing that 
PM muscle volume independently predicts mortality.2
Is Lactate Dehydrogenase C Limiting 
Anaerobic Metabolism?
Patients with CHF have an increased reliance on an-
aerobic metabolism for a given exercise work load 
compared with matched controls,12 which is caused 
by significant limitations to mitochondrial oxidative 
metabolism (Figure 1). Our RNA-seq analysis showed 
that the glycolytic enzyme lactate dehydrogenase C 
was severely downregulated by 46-fold in patients 
with CHF versus controls (Figure 3C and 3D), which 
is consistent with earlier work3,12 and indicates dis-
ruptions to NAD+/NADH homeostasis in CHF skel-
etal muscle. Overall, these data implicate a specific 
impairment at the transcriptional level of the lactate 
dehydrogenase enzyme and identify components of 
both oxidative and glycolytic metabolic machinery to 
be perturbed in CHF.
Is AMPD3 a Mediator of Impaired 
Metabolism and Fiber Atrophy?
The AMPD3 gene showed the highest upregulation 
in CHF by 3-fold (Figure 3C and 3D), which indicates 
a shift toward a greater reliance on the AMP deami-
nase reaction in skeletal muscle of patients with CHF. 
AMPD3 catalyzes the first and rate-limiting step of the 
purine nucleotide cycle, highlighting its role as a key 
enzyme muscle energetics and amino acid catabo-
lism. Under metabolic stress, AMP levels increase as 
ADP is converted to ATP and AMP via the adenylate 
kinase reaction, which maintains a high ATP/ADP 
ratio. AMP is then irreversibly deaminated by AMP 
deaminase to inosine monophosphate and ammo-
nia. In vivo evidence confirms intramuscular concen-
tration of ADP are higher and Phosphocreatine (PCr) 
and pH are lower for given work rates in patients with 
CHF,12,13 which could explain our transcriptome find-
ings that AMPD3 expression is increased to com-
pensate under metabolic stress where ATP is low 
(Figures 1 through 3).12,13 AMP activates glycolytic me-
tabolism and this mechanism is likely impaired given 
the capacity of glycolytic enzymes is lower in muscle 
from patients with CHF.3,12 Increased reliance on AMP 
deaminase would increase inosine monophosphate 
and ammonia formation while lowering the total ad-
enine nucleotide pool thereby exacerbating muscle 
fatigue. Elevated levels of inosine monophosphate 
are converted back to AMP by combining with the 
amino acid aspartate via the purine nucleotide cycle. 
Increased expression of AMPD3 in skeletal muscle 
of patients with CHF may reflect a fuel shift toward 
increased catabolism of amino acids and thus pro-
vide a novel mechanism linking metabolic dysregula-
tion and muscle wasting in patients with CHF given 
AMPD3 is upregulated in various atrophic conditions 
in animal models such as disuse, starvation, cancer, 
and denervation.14 Here, we translate this to humans 
with CHF.
Does PYROXD2 Link to Mitochondrial 
Dysfunction and Myopathy?
PYROXD2 was upregulated by 2.5-fold in patients 
with CHF (Figure 3C and 3D). The physiological role 
of PYROXD2, particularly in skeletal muscle, remains 
largely unclear but recent data show that genetic var-
iants in its family member PYROXD1 induces early-
onset myopathy and limb girdle muscular dystrophy 
characterized by abnormal myofibrils, nuclei, and 
mitochondria.15 PYROXD2 is part of a pyridine nu-
cleotide-disulfide oxidoreductase domain-containing 
protein family that is involved in redox and energy 
balance. Pyridine nucleotidedisulphide reductases 
are flavoproteins (FAD binding) that catalyze the pyri-
dine nucleotide (NAD/NADH)-dependent reduction 
of cysteine residues in their substrates,15 implicat-
ing a role for impaired NAD+/NADH homeostasis. 
PYROXD2 (also known as YueF) can also induce 
the expression of the transcription factor p53,16 with 
the latter known to promote fiber atrophy in various 
conditions including limb immobilization and cancer 
cachexia.17 Overall, these studies identify PYROXD2 
as a potential regulator of muscle homeostasis in pa-
tients with CHF by controlling metabolic homeosta-
sis, mitochondrial function, and fiber atrophy via a 
redox-dependent pathway.
Study Limitations
Our analyses were performed in a relatively small 
sample size, mostly men and patients with a reduced 
ejection fraction, so should be viewed with caution 
when generalizing to the larger population of patients 
with CHF. In addition, our in situ mitochondrial res-
piration measurements may not reflect the in vivo 
muscle environment in patients, given some of the 
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experimental settings such as O2 and substrate (eg, 
ADP) concentrations where unphysiological (as de-
tailed elsewhere18), which may limit translation. We 
have also inferred that mitochondrial impairments in 
skeletal muscle are likely contributing to symptoms of 
exercise intolerance to a greater degree than those 
related to cardiac dysfunction, as based on our cor-
relative data. This suggestion is supported by clear 
data showing that exercise intolerance (ie, VO2peak) in 
patients with CHF poorly correlates with measures of 
cardiac dysfunction, while in contrast skeletal mus-
cle impairments are closely associated.19 We also 
acknowledge that some variance in our results may 
be explained, at least in part, by other confounding 
factors such as sex, age, and levels of physical activ-
ity.4,20 As such, future studies should carefully control 
for potential confounding factors that may have im-
pacted our current results.
CONCLUSIONS
We believe this is the first study to demonstrate that 
patients with CHF are characterized by a unique tran-
scriptome signature in skeletal muscle that is under-
pinned by a metabolic myopathy in both the upper 
and lower limbs, which closely associated with worse 
symptoms. These findings have important implica-
tions for our understanding of the skeletal muscle pa-
thology and its relation to symptoms in patients with 
CHF.
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Data S1. 
Muscle biopsy 
Samples were taken from two sites in participants, including from the upper limb (pectoralis 
major) and lower limb (vastus lateralis). Pectoralis major sample was obtained during routine 
device implantation procedures, while on the same day a vastus lateralis sample of the right 
thigh were obtained using the Bergström needle method modified to allow for suction. The 
sample region was cleaned beforehand with iodine and anaesthetised (1% lidocaine), while 
the wound was closed with surgical tape strips and a soft adhesive sterile dressing. Biopsies 
were taken within 3 months following study recruitment and collection of baseline clinical data. 
There were no complications or adverse events with any of the research procedures. One 
piece of muscle sample was immediately placed in 1 mL of ice-cold specialized preservation 
solution termed BIOPS4 for assessment of mitochondrial respiration while another small 
portion was rapidly frozen in a small subset for RNA sequencing.  
Mitochondrial function 
Mitochondrial respiration was assessed in situ from saponin-permeabilized skeletal muscle 
fibres using high-resolution respirometry (Oxygraph-2K; Oroboros Instruments, Innsbruck, 
Austria), as previously described4. Briefly, in the following order: 1) complex I Leak respiration 
was determined by addition of glutamate (10 mM), malate (0.5 mM) and pyruvate (5 mM) (i.e., 
a measure of proton leak under non-phosphorylating conditions); 2) adenosine diphosphate 
(ADP; 2.5 mM) added to provide a measure of complex I oxidative phosphorylation 
(OXPHOS); 3) outer mitochondrial membrane integrity determined by addition of 10 μM 
cytochrome c; 4) succinate at 10 mM as a complex II substrate provided complex I+II 
OXPHOS; 4) 5 μM carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP) for 
maximal uncoupled complex I+II respiration; 5) complex I inhibitor rotenone at 0.25 μM 
provided uncoupled complex II respiration; and 6) 2.5 μM antimycin A as a complex III inhibitor 
for residual oxygen consumption (ROX) to calculate non-mitochondrial (background) 
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respiration, which was then used to normalise the data. Mitochondrial content was determined 
within the respirometer using a complex IV activity assay (a close proxy)4 by the addition of 
0.5 mM N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride (TMPD) as an artificial 
electron donor to complex IV in combination with 2 mM ascorbate to maintain TMPD in a 
reduced state. Absolute mitochondrial respiration was normalised to complex IV activity to 
provide an index of mitochondrial intrinsic function.  
RNA isolation and sequencing 
In a subset of patients (CON = 3; CHF = 6) biopsies were immediately transferred to a clean 
2 ml screw-capped tube and flash-frozen in liquid nitrogen. A small piece of tissue (~30 to 50 
mg) was added to a 2 ml microcentrifuge tube containing a stainless-steel bead and 1 ml 
TRIzol (Invitrogen, UK). The tissue was homogenized using a TissueLyser (Qiagen, UK) at 
frequency 25 Hz for 2 minutes. RNA was extracted from the homogenate with TRIzol using 
standard protocols. Nine RNA samples were treated with DNase I using the RNA Clean and 
Concentrator kit (Zymo Research, UK). The quality of the RNA was evaluated on a DeNovix 
DS-11 FX + Spectrophotometer / Fluorometer (DeNovix, USA) as per manufacturer’s 
instruction. RNA was considered of high quality when A260/A280 and A260/A230 ratios achieved 
2.0. Subsequently, Agilent 2100 Bioanalyzer (Agilent Technology, USA) was used to measure 
RNA integrity number (RIN). Nine RNA samples achieved RIN value >7.5 and proceeded with 
RNA sequencing (RNA-seq). RNA-seq was performed using the TruSeq RNA library 
preparation kit at the Cambridge Genomics Services. The RNA-seq libraries were sequenced 
on the NextSeq 500 platform in a single lane, generating ~16 million single-end 75 bp reads 
for each sample (Table 4). All the protocols were carried out according to the manufacturer’s 
recommendations. The raw reads were deposited at the ArrayExpress domain 
(https://www.ebi.ac.uk/arrayexpress/) under the accession E-MTAB-8531. 
Bioinformatics processing 
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Bioinformatics processing followed detailed methods published elsewhere.10 Raw sequences 
in FASTQ format were downloaded from the sequencing centre. Quality control of the raw 
sequences were performed using FastQC v0.118 to evaluate the overall quality. The raw 
sequences were manipulated using TrimGalore v0.6.2 to remove the adapter sequences and 
low-quality sequences. Next, clean reads were mapped to the human reference genome 
(GRCh38 Homo sapiens reference genome release 96) using STAR v2.7 aligner. To improve 
the quality of the data, only uniquely mapping reads with a mapping quality score 255 were 
counted. Post-alignment quality control was carried out on all aligned BAM files. featureCounts 
v1.6.5 was used to quantify the read counts of each gene for the subsequently differential 
expression analysis. The expression profile of each gene was expressed as read counts.  
Differential expression analysis 
The raw read counts were used as an input for DESeq2 v1.26, an R/Bioconductor package 
for differential expression analysis. DESeq2 normalizes the raw read counts based on the 
median of rations as described previously. Partial least squares discriminant analysis (PLS-
DA), a supervised method implemented in mixOmics v6.10.2 was performed. PLS-DA was 
used to classify nine patients based on the DESeq2 normalized counts for 18,426 genes. Two 
clusters in the PLS-DA plot consistently placed the nine samples into two groups. Recently, 
PLS-DA has been adapted to RNA-seq data to provide transcriptome expression landscape 
due to its ability to discriminate sample artefacts. Differentially expressed genes (DEGs) were 
conducted in a pairwise manner, using DESeq2. Genes achieving a false discovery rate (FDR) 
threshold below 0.05 were considered significantly differentially expressed. The full gene 
list is attached in Table S5. Volcano plot and heatmap of DEGs were constructed using 
the ggplot2 package and ‘pheatmap’ function implemented in R, respectively.  
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Table S1. Demographic and clinical characteristics of cohort. 
CHF (n=28) 
(
CON (n=9) P-value
Demographics 
Male sex [n (%)] 26 (93) 6 (67) 0.046 
Age (years) 69.3±2.3 75.4±2.0 0.055 
Weight (kg) 85.9±3.6 80.3±4.3 0.405 
Height (m) 1.7±0.02 1.7±0.04 0.443 
BMI (kg·m2) 29.5±0.9 26.9±1.3 0.156 
Clinical characteristics 
NYHA class [n (%)]  
 I 2 (7) 9 (100) <0.001 
 II 16 (57) 0 (0) 
 III 10 (36) 0 (0) 
IHD  [n (%)] 16 (57) 2 (22) 0.068 
DCM [n (%)] 10 (36) 0 (0) 0.036 
AF [n (%)] 10 (36) 3 (33) 0.896 
CABG [n (%)] 5 (18) 1 (11) 0.633 
HTN [n (%)] 11 (39) 4 (44) 0.784 
COPD [n (%)] 0 (0) 1 (11) 0.074 
LVEF (%) 28.6±2.4 51.4±1.5 <0.001 
LVIDd (mm) 49.9±2.4 31.4±2.4 <0.001 
Hb (g·L⁻1) 141.7±3.0 129.9±6.6 0.073 
Na (mmol·L⁻1) 139.7±0.6 140.6±0.9 0.490 
K (mmol·L⁻1) 4.6±0.1 4.5±0.3 0.629 
Creatinine (µmol·mL⁻1) 98.1±4.9 84.3±2.8 0.123 
eGFR (mL·min⁻1·1.73 m-2) 64.8±3.8 71.1±5.1 0.395 
Glucose (mmol·L⁻1) 9.0±3.2 5.2±5.1 0.495 
HbA1c (mmol·mol⁻1) 32.9±5.1 26.8±6.7 0.540 
Data are mean±SEM and were assessed by unpaired Student’s t-test. BMI, body mass index; 
V̇O2peak, peak pulmonary consumption; NYHA, New York Heart Association; IHD, ischaemic 
heart disease; DCM, dilated cardiomyopathy; AF, atrial fibrillation; CABG, coronary artery 
bypass graft; HTN, hypertension; COPD, chronic obstructive pulmonary disease; LVEF, left 
ventricular ejection fraction; LVIDs, left ventricular internal diameter in systole; LVIDd, left 
ventricular internal diameter in diastole; Hb, haemoglobin; Na, serum sodium; K, serum 
potassium; eGFR, estimated glomerular filtration rate; NT-pro-BNP, N-terminal pro hormone 
B-type natriuretic peptide; HbA1c, glycated haemoglobin.
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Table S2. Medications and device therapy. 
CHF (n=28) 
(
CON (n=9) P-value
Medications 
ACEi [n (%)] 22 (79) 2 (22) 0.002 
Beta-blocker [n (%)] 27 (96) 1 (11) <0.001 
Furosemide equivalent dose (mg) 33.6 ± 6.4 8.9 ± 8.9 0.055 
ARB [n (%)] 5 (18) 1 (11) 0.633 
MRA [n (%)] 13 (46) 1 (11) 0.057 
Statin [n (%)] 20  (71) 6 (67) 0.786 
Antiplatelet [n (%)] 14 (50) 1 (11) 0.039 
Metformin [n (%)] 6 (75) 0 (0) 0.129 
Insulin [n (%)] 2 (7) 0 (0) 0.410 
Sulphonylurea [n (%))] 3 (11) 0 (0) 0.306 
Anticoagulant [n (%)] 7 (25) 5 (56) 0.218 
Digoxin [n (%)] 4 (14) 0 (0) 0.230 
Ivabradine [n (%)] 1 (4) 0 (0) 0.565 
Device therapy 
PPM [n (%)] 0 (0) 9 (100) <0.001 
ICD [n (%)] 6 (21) 0 (0) 0.129 
CRT [n (%)] 22 (79) 0 (0) <0.001 
Continuous variables are presented as mean±SEM, categorical variables as number (%) and 
were assessed by unpaired Student’s t-test. ACEi, angiotensin-converting enzyme inhibitor; 
ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; PPM, 
permanent pacemaker; ICD, implantable cardioverter defibrillator; CRT, cardiac 
resynchronisation therapy.  
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Table S3. Demographic and clinical characteristics for participants included in the 
RNAseq analysis. 
CHF (n=6) 
(
CON (n=3) P-value
Demographics 
Male sex [n (%)] 6 (100) 2 (67) 0.13 
Age (years) 76.7 ± 3.3 80.2 ± 2.6 0.51 
Weight (kg) 77.2 ± 7.5 74.5 ± 20.7 0.85 
Height (m) 1.7 ± 0.05 1.7 ± 0.1 0.62 
BMI (kg·m2) 27.6 ± 1.7 24.9 ± 1.9 0.37 
Clinical characteristics 
NYHA class 
 I 2 (33) 3 (100) 0.17 
 II 2 (33) 0 (0) 
 III 2 (33) 0 (0) 
IHD [n (%)] 3 (50) 1 (33) 0.64 
DCM [n (%)] 3 (50) 0 (0) 0.13 
AF [n (%)] 3 (50) 1 (33) 0.64 
CABG [n (%)] 2 (33) 1 (33) 1.0 
HTN [n (%)] 3 (50) 3 (100) 0.13 
COPD [n (%)] 0 (0) 1 (33) 0.13 
LVEF (%) 26.3 ± 5.6 50.8 ± 3.0 0.006 
LVIDd (mm) 56.5 ± 3.6 49.7 ± 2.4 0.26 
Hb (g·L⁻1) 143.0 ± 3.7 114 ± 13.9 0.029 
Na (mmol·L⁻1) 143.0 ± 1.0 138.7 ± 1.2 0.039 
K (mmol·L⁻1) 4.3 ± 0.2 4.4 ± 0.7 0.88 
Creatinine (µmol·mL⁻1) 96.7 ± 8.5 86.0 ± 7.0 0.45 
eGFR (mL·min⁻1·1.73 m-
2)
67.7 ± 6.9 69.0 ± 12.1 0.92 
HbA1c (mmol·mol⁻1) 39.4 ± 1.2 44.0 - 
Continuous variables are presented as mean ± SEM, categorical variables as number (%). 
BMI, body mass index; V̇O2peak, peak pulmonary consumption; NYHA, New York Heart 
Association; IHD, ischaemic heart disease; DCM, dilated cardiomyopathy; AF, atrial fibrillation; 
CABG, coronary artery bypass graft; HTN, hypertension; COPD, chronic obstructive 
pulmonary disease; LVEF, left ventricular ejection fraction; LVIDs, left ventricular internal 
diameter in systole; LVIDd, left ventricular internal diameter in diastole; Hb, haemoglobin; Na, 
serum sodium; K, serum potassium; eGFR, estimated glomerular filtration rate; NT-pro-BNP, 
N-terminal pro hormone B-type natriuretic peptide; HbA1c, glycated haemoglobin.
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Table S4. Summary statistics of RNA sequencing, total number of reads generated, read 
mapping to the GRCh38 Homo sapiens reference genome, RNA integrity number (RIN), 
for nine RNA samples. 
Sample Raw reads Unique reads 
Percentage of 
mapped reads 
RIN score 
SKM_C_1 16216274 15022715 92.64 8 
SKM_C_2 18364747 16835780 91.67 7.5 
SKM_C_3 20400222 18670124 91.52 8.2 
SKM_HF_1 14233566 13140795 92.32 8.6 
SKM_HF_2 16437260 15135973 92.08 8.8 
SKM_HF_3 14932640 13646610 91.39 7.6 
SKM_HF_4 15333154 14116260 92.06 8.5 
SKM_HF_5 14537174 13352387 91.85 8.9 
SKM_HF_6 15308095 14092935 92.06 7.9 
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Table S5. Gene database. Please see Excel file.
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Table S6. Demographic and clinical characteristics from two apparently distinct 
clusters of patients with CHF derived from the RNAseq analysis. 
Cluster 1 (1,3,4) 
(
Cluster 2 (2,5,6) P-value
Demographics 
Male sex [n (%)] 3 (100) 3 (100) 1.0 
Age (years) 76.1 ± 12.6 77.2 ± 0.8 0.88 
Weight (kg) 80.7 ± 7.2 73.7 ± 27.6 0.69 
Height (m) 1.7 ± 0.1 1.6 ± 0.2 0.68 
BMI (kg·m2) 28.3 ± 2.9 26.8 ± 5.8 0.70 
Clinical characteristics 
NYHA class [n (%)] 
 I 0 (0) 2 (67) 0.14 
 II 1 (33) 1 (33) 
 III 2 (67) 0 (0) 
IHD  [n (%)] 2 (67) 1 (33) 0.41 
DCM [n (%)] 1 (33) 2 (67) 0.41 
AF [n (%)] 1 (33) 2 (67) 0.41 
CABG [n (%)] 1 (33) 1 (33) 1.0 
HTN [n (%)] 2 (67) 1 (33) 0.41 
COPD [n (%)] 0 (0) 0 (0) . 
LVEF (%) 38.3 ± 5.8 14.2 ± 1.4 0.002 
LVIDd (mm) 52.0 ± 7.8 61.0 ± 8.7 0.25 
Hb (g·L⁻1) 138.7 ± 4.0 147.3 ± 11.5 0.29 
Na (mmol·L⁻1) 144.3 ± 2.5 141.7 ± 2.1 0.23 
K (mmol·L⁻1) 4.2 ± 0.5 4.3 ± 0.6 0.84 
Creatinine (µmol·mL⁻1) 85.7 ± 22.1 107.7 ± 15.5 0.23 
eGFR (mL·min⁻1·1.73 m-2) 76.7 ± 19.1 58.7 ± 10.8 0.23 
HbA1c (mmol·mol⁻1) 40.0 ± 3.6 38.5 ± 2.1 0.64 
Data are mean±SEM and were assessed by unpaired Student’s t-test. BMI, body mass index; 
V̇O2peak, peak pulmonary consumption; NYHA, New York Heart Association; IHD, ischaemic 
heart disease; DCM, dilated cardiomyopathy; AF, atrial fibrillation; CABG, coronary artery 
bypass graft; HTN, hypertension; COPD, chronic obstructive pulmonary disease; LVEF, left 
ventricular ejection fraction; LVIDs, left ventricular internal diameter in systole; LVIDd, left 
ventricular internal diameter in diastole; Hb, haemoglobin; Na, serum sodium; K, serum 
potassium; eGFR, estimated glomerular filtration rate; NT-pro-BNP, N-terminal pro hormone 
B-type natriuretic peptide; HbA1c, glycated haemoglobin.
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